Literature DB >> 11297702

Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease.

P W Serruys1, F Unger, J E Sousa, A Jatene, H J Bonnier, J P Schönberger, N Buller, R Bonser, M J van den Brand, L A van Herwerden, M A Morel, B A van Hout.   

Abstract

BACKGROUND: The recent recognition that coronary-artery stenting has improved the short- and long-term outcomes of patients treated with angioplasty has made it necessary to reevaluate the relative benefits of bypass surgery and percutaneous interventions in patients with multivessel disease.
METHODS: A total of 1205 patients were randomly assigned to undergo stent implantation or bypass surgery when a cardiac surgeon and an interventional cardiologist agreed that the same extent of revascularization could be achieved by either technique. The primary clinical end point was freedom from major adverse cardiac and cerebrovascular events at one year. The costs of hospital resources used were also determined.
RESULTS: At one year, there was no significant difference between the two groups in terms of the rates of death, stroke, or myocardial infarction. Among patients who survived without a stroke or a myocardial infarction, 16.8 percent of those in the stenting group underwent a second revascularization, as compared with 3.5 percent of those in the surgery group. The rate of event-free survival at one year was 73.8 percent among the patients who received stents and 87.8 percent among those who underwent bypass surgery (P<0.001 by the log-rank test). The costs for the initial procedure were $4,212 less for patients assigned to stenting than for those assigned to bypass surgery, but this difference was reduced during follow-up because of the increased need for repeated revascularization; after one year, the net difference in favor of stenting was estimated to be $2,973 per patient.
CONCLUSION: As measured one year after the procedure, coronary stenting for multivessel disease is less expensive than bypass surgery and offers the same degree of protection against death, stroke, and myocardial infarction. However, stenting is associated with a greater need for repeated revascularization.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11297702     DOI: 10.1056/NEJM200104123441502

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  142 in total

1.  Intracoronary stenting: developments since the NICE report.

Authors:  A H Gershlick
Journal:  Heart       Date:  2002-03       Impact factor: 5.994

2.  Is surgery still the preferred option for coronary revascularisation in diabetics with multivessel coronary disease?

Authors:  A Kapur; I S Malik
Journal:  Heart       Date:  2002-05       Impact factor: 5.994

3.  Angioplasty, bypass surgery or medical treatment: how should we decide?

Authors:  J P Pell; M A Denvir
Journal:  Heart       Date:  2002-11       Impact factor: 5.994

4.  Percutaneous coronary intervention in diabetics: time to consider "intimal remodelling therapy"?

Authors:  P F Ludman
Journal:  Heart       Date:  2002-09       Impact factor: 5.994

Review 5.  Chronic stable angina: treatment options.

Authors:  Laurence O'Toole; Ever D Grech
Journal:  BMJ       Date:  2003-05-31

6.  Drug eluting stents: maximising benefit and minimising cost.

Authors:  J Gunn; A C Morton; C Wales; C M H Newman; D C Crossman; D C Cumberland
Journal:  Heart       Date:  2003-02       Impact factor: 5.994

Review 7.  New developments in percutaneous coronary intervention.

Authors:  Julian Gunn; David Crossman; Ever D Grech; David Cumberland
Journal:  BMJ       Date:  2003-07-19

8.  Revascularisation for acute coronary syndromes: PCI or CABG?

Authors:  J Gunn; D P Taggart
Journal:  Heart       Date:  2003-09       Impact factor: 5.994

Review 9.  Perspectives of I(f) inhibition by ivabradine in cardiology.

Authors:  Michael Böhm; Jan-Christian Reil
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 10.  The role of PCI and CABG in the management of coronary artery disease in patients with diabetes.

Authors:  Robert L Frye; Malcolm R Bell; Hartzell V Schaff; Richard Holubkov; Katherine M Detre
Journal:  Curr Diab Rep       Date:  2002-02       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.